Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Oligodendroglioma 1Gliosarcoma 1Glioma 1Glioblastoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 12Bevacizumab 8Carboplatin 6Radiotherapy 5Erlotinib Hydrochloride 5temsirolimus 3Surgical Procedures, Operative 3Irinotecan 3IL13-PE38 3veliparib 2pembrolizumab 2etoposide phosphate 2Vorinostat 2Specimen Handling 2Sirolimus 2Radiotherapy, Intensity-Modulated 2Radiotherapy, Conformal 2Radiation 2Magnetic Resonance Spectroscopy 2Imatinib Mesylate 2Genetic Therapy 2Everolimus 2Cetuximab 2Carmustine 2Cancer Vaccines 2trastuzumab deruxtecan 1transforming growth factor(alpha)-Pseudomonas aeruginosa exotoxin (38) 1terameprocol 1sonidegib 1sodium thiosulfate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Astrocytoma × octadecyl-(N,N-dimethylpiperidino-4-yl)-phosphate × Clear all
NCT01051557 2021-07-19

Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma

National Cancer Institute (NCI)

Phase 1/2 Completed
36 enrolled 15 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡